Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar

Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock.

The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share price return decline of 19.49%. At the same time, the 1-year total shareholder return of 135% and the very large 3-year total shareholder return of more than 5x suggest that longer term momentum has been strong and may frame the guidance upgrade as a potential reset of growth expectations rather than a complete change in sentiment.

If Xeris’ story has your attention, it can be useful to see what else is moving in healthcare. You can start with healthcare stocks as a source of fresh ideas.

With Xeris trading at US$7.52, a value score of 4, and an indicated discount to analyst targets, the key question is simple: is this an opportunity to invest in potential future growth, or is the market already pricing it in?

Most Popular Narrative: 34.6% Undervalued

With Xeris Biopharma Holdings’ fair value in the narrative set at US$11.50 against a last close of US$7.52, the valuation gap is clear and rests heavily on how durable future cash generation proves to be.

The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation, potentially driving new revenue streams and long-term margin expansion.

Curious what kind of revenue ramp and profit margin shift are baked into that US$11.50 figure? The narrative leans on compound growth, margin expansion, and a future earnings multiple that many investors usually associate with more mature peers. Want to see exactly how those assumptions stack together?

Result: Fair Value of $11.50 (UNDERVALUED)

However, the story could change quickly if XP-8121 stumbles in late stage trials or if competitors squeeze Recorlev in the hypercortisolism market.

Build Your Own Xeris Biopharma Holdings Narrative

If you see the numbers differently or prefer to work from your own assumptions, you can build a custom Xeris view in minutes, starting with Do it your way.

A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Xeris has sparked your interest, do not stop here. Use the Simply Wall St screener to spot other opportunities that could fit your approach.

• Jump on potential mispricings by scanning these 873 undervalued stocks based on cash flows that may not yet be fully reflected in their share prices.
• Tap into future facing themes by checking out these 24 AI penny stocks that are linked to artificial intelligence trends.
• Target income focused opportunities by reviewing these 12 dividend stocks with yields > 3% that currently offer yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.